Amgen

News

Amgen nabs speedy approval for first-ever KRAS drug sotorasi...

After decades of mostly unsuccessful R&D, Amgen has claimed the first ever regulatory approval for a drug that inhibits KRAS – a cancer target that for a long time was all-but written o

News

Ex-Merck R&D chief Perlmutter takes reins at drug discovery ...

A new drug discovery firm, Eikon Therapeutics, has launched with former Merck & Co research chief Roger Perlmutter at the helm.

News

BMS' deucravacitinib psoriasis pill could launch next year a...

Bristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in patients with moderate to severe disease.

News

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer and MD Anderson extend KRAS cancer collaboration

Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center have extended and expanded a collaboration exploring medicines targeting lung cancer with KRAS mutations.

News

Amgen buys inflammatory diseases drug firm Rodeo for up to $...

Amgen has announced its second acquisition in the space of a month, snapping up Rodeo Therapeutics and its potential tissue repair drugs in a deal worth up to $721 million.

News